Lack of effect of guideline changes on LDL cholesterol reporting and control for diabetes visits in the U.S., 1995-2004.
Wang
Y Richard
YR
Public Policy Department, AstraZeneca Pharmaceuticals, FOC 3 CE 417, 1800 Concord Pike, Wilmington, DE 19850-5437, USA. y.richard.wang@astrazeneca.com
Alexander
G Caleb
GC
Meltzer
David O
DO
D008078:Cholesterol, LDL / Q000097:blood*; D003327:Coronary Disease / Q000097:blood* / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000097:blood* / Q000517:prevention & control; D006801:Humans; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D014481:United States
D008078:Cholesterol, LDL